Published online before print September 18, 2006, doi: 10.1161/CIRCULATIONAHA.105.607135
(Circulation. 2006;114:1403-1409.)
© 2006 American Heart Association, Inc.
Molecular Cardiology |
High-Density Lipoproteins and Their Constituent, Sphingosine-1-Phosphate, Directly Protect the Heart Against Ischemia/Reperfusion Injury In Vivo via the S1P3 Lysophospholipid Receptor
From the Institute for Anatomy (G.T., I.H., J.M., J.L., R.H., C.H., M. Schmitz), Department of Anesthesiology and Intensive Care (G.T., C.S., I.H., J.M., J.L., C.H.), Department of Nuclear Medicine (M. Schäfers, S.H., O.S.), and Department of Cardiology and Angiology (J.S.), IZKF Münster, University Hospital, Münster, Germany; Department of Internal Medicine (J.H.), Mayo Clinic, Rochester, Minn; Institute of Pathophysiology, Center of Internal Medicine (P.K., R.S., G.H., K.v.W.L., B.L.) and Department of Cardiology (M.H., R.E.), West German Heart Center, University Hospital, Essen, Germany; and Department of Molecular Biology (J.C.), Helen L. Dorris Child and Adolescent Neuropsychiatric Disorder Institute, The Scripps Research Institute, La Jolla, Calif.
Correspondence to Bodo Levkau, MD, Institute of Pathophysiology, Center of Internal Medicine, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany (e-mail levkau{at}uni-essen.de), or Gregor Theilmeier, MD, Institute for Anatomy, Department of Anesthesiology and Intensive Care, University Hospital Münster, Vesaliusweg 2-4, 48149 Münster, Germany (e-mail theilmeier@anit.uni-muenster.de).
Received December 9, 2005; revision received July 25, 2006; accepted July 27, 2006.
Background— All treatments of acute myocardial infarction are aimed at rapid revascularization of the occluded vessel; however, no clinical strategies are currently available to protect the heart from ischemia/reperfusion injury after restitution of blood flow. We hypothesized that some of the cholesterol transport–independent biological properties of high-density lipoprotein (HDL) implied in atheroprotection may also be beneficial in settings of acute myocardial reperfusion injury.
Methods and Results— In an in vivo mouse model of myocardial ischemia/reperfusion, we observed that HDL and its sphingolipid component, sphingosine-1-phosphate (S1P), dramatically attenuated infarction size by 
20% and 40%, respectively. The underlying mechanism was an inhibition of inflammatory neutrophil recruitment and cardiomyocyte apoptosis in the infarcted area. In vitro, HDL and S1P potently suppressed leukocyte adhesion to activated endothelium under flow and protected rat neonatal cardiomyocytes against apoptosis. In vivo, HDL- and S1P-mediated cardioprotection was dependent on nitric oxide (NO) and the S1P3 lysophospholipid receptor, because it was abolished by pharmacological NO synthase inhibition and was completely absent in S1P3-deficient mice.
Conclusions— Our data demonstrate that HDL and its constituent, S1P, acutely protect the heart against ischemia/reperfusion injury in vivo via an S1P3-mediated and NO-dependent pathway. A rapid therapeutic elevation of S1P-containing HDL plasma levels may be beneficial in patients at high risk of acute myocardial ischemia.
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  M. A. Frias, U. Lang, C. Gerber-Wicht, and R. W. James Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis Cardiovasc Res, January 1, 2010; 85(1): 118 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Takuwa, S.-I. Ohkura, S.-I. Takashima, K. Ohtani, Y. Okamoto, T. Tanaka, K. Hirano, S. Usui, F. Wang, W. Du, et al. S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species Cardiovasc Res, October 6, 2009; (2009) cvp312v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Vessey, L. Li, N. Honbo, and J. S. Karliner Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and postconditioning Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1429 - H1435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J.E. Sattler, J. Herrmann, S. Yun, N. Lehmann, Z. Wang, G. Heusch, S. Sack, R. Erbel, and B. Levkau High high-density lipoprotein-cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention Eur. Heart J., August 1, 2009; 30(15): 1894 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Frias, R. W. James, C. Gerber-Wicht, and U. Lang Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: Role of sphingosine-1-phosphate Cardiovasc Res, May 1, 2009; 82(2): 313 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sattler and B. Levkau Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection Cardiovasc Res, May 1, 2009; 82(2): 201 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Igarashi and T. Michel Sphingosine-1-phosphate and modulation of vascular tone Cardiovasc Res, May 1, 2009; 82(2): 212 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Means and J. H. Brown Sphingosine-1-phosphate receptor signalling in the heart Cardiovasc Res, May 1, 2009; 82(2): 193 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Skoura and T. Hla Regulation of vascular physiology and pathology by the S1P2 receptor subtype Cardiovasc Res, May 1, 2009; 82(2): 221 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Skoura and T. Hla Lysophospholipid receptors in vertebrate development, physiology, and pathology J. Lipid Res., April 1, 2009; 50(Supplement): S293 - S298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Shaw, A. Bobik, A. Murphy, P. Kanellakis, P. Blombery, N. Mukhamedova, K. Woollard, S. Lyon, D. Sviridov, and A. M. Dart Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque Circ. Res., November 7, 2008; 103(10): 1084 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Takabe, S. W. Paugh, S. Milstien, and S. Spiegel "Inside-Out" Signaling of Sphingosine-1-Phosphate: Therapeutic Targets Pharmacol. Rev., June 1, 2008; 60(2): 181 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Means, S. Miyamoto, J. Chun, and J. H. Brown S1P1 Receptor Localization Confers Selectivity for Gi-mediated cAMP and Contractile Responses J. Biol. Chem., May 2, 2008; 283(18): 11954 - 11963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Oyama, N. Sugimoto, X. Qi, N. Takuwa, K. Mizugishi, J. Koizumi, and Y. Takuwa The lysophospholipid mediator sphingosine-1-phosphate promotes angiogenesis in vivo in ischaemic hindlimbs of mice Cardiovasc Res, May 1, 2008; 78(2): 301 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gomaraschi, L. Calabresi, G. Rossoni, S. Iametti, G. Franceschini, J. A. Stonik, and A. T. Remaley Anti-Inflammatory and Cardioprotective Activities of Synthetic High-Density Lipoprotein Containing Apolipoprotein A-I Mimetic Peptides J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 776 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kim, M. Kim, N. Kim, V. D. D'Agati, C. W. Emala Sr, and H. T. Lee Isoflurane mediates protection from renal ischemia-reperfusion injury via sphingosine kinase and sphingosine-1-phosphate-dependent pathways Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1827 - F1835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Argraves and W. S. Argraves HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects J. Lipid Res., November 1, 2007; 48(11): 2325 - 2333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, N. Honbo, E. J. Goetzl, K. Chatterjee, J. S. Karliner, and M. O. Gray Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3150 - H3158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nishino, I. Webb, and M. S. Marber Sphingosine kinase isoforms and cardiac protection Cardiovasc Res, October 1, 2007; 76(1): 3 - 4. [Full Text] [PDF]
|
|
|
|
|
|
C. K. Means, C.-Y. Xiao, Z. Li, T. Zhang, J. H. Omens, I. Ishii, J. Chun, and J. H. Brown Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2944 - H2951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Xia Letter by Xia Regarding Article, "High-Density Lipoproteins and Their Constituent, Sphingosine-1-Phosphate, Directly Protect the Heart Against Ischemia/Reperfusion Injury In Vivo via the S1P3 Lysophospholipid Receptor" Circulation, April 10, 2007; 115(14): e393 - e393. [Full Text] [PDF]
|
|
|
|
|
|
G. Theilmeier, C. Schmidt, J. Herrmann, P. Keul, M. Schafers, I. Herrgott, J. Mersmann, J. Larmann, S. Hermann, J. Stypmann, et al. Response to Letter Regarding Article, "High-Density Lipoproteins and Their Constituent, Sphingosine-1-Phosphate, Directly Protect the Heart Against Ischemia/Reperfusion Injury In Vivo via the S1P3 Lysophospholipid Receptor" Circulation, April 10, 2007; 115(14): e394 - e394. [Full Text] [PDF]
|
|
|
|
|
|
Q. Yang Chasing sphingosine-1-phosphate, a lipid mediator for cardiomyocyte survival Cardiovasc Res, April 1, 2007; 74(1): 4 - 5. [Full Text] [PDF]
|
|
|
|
|
|
J.-R. Nofer, M. Bot, M. Brodde, P. J. Taylor, P. Salm, V. Brinkmann, T. van Berkel, G. Assmann, and E. A.L. Biessen FTY720, a Synthetic Sphingosine 1 Phosphate Analogue, Inhibits Development of Atherosclerosis in Low-Density Lipoprotein Receptor Deficient Mice Circulation, January 30, 2007; 115(4): 501 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Maceyka, S. Milstien, and S. Spiegel Shooting the Messenger: Oxidative Stress Regulates Sphingosine-1-Phosphate Circ. Res., January 5, 2007; 100(1): 7 - 9. [Full Text] [PDF]
|
|